Parexel International Corporati (NASDAQ:PRXL)

Mr. von Rickenbach continued, 'I remain confident regarding PAREXEL's prospects for the future, and believe that our global footprint, and a diverse service offering have positioned us well for the current environment. Revenue growth has been quite healthy, especially on a same-store, constant currency basis. The steps that we have taken over the past year to better leverage our global presence in managing our own costs have been paying off, and we still have a number of initiatives underway which we expect will continue to drive revenue growth and profitability in the coming quarters. On a final note, the integration of ClinPhone is tracking well, and we expect further progress as we go forward.'

^a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.

^b Non-GAAP EPS figures generally exclude certain non-operating gains and losses as well as certain non-cash items. Non-GAAP information should not be viewed in isolation or as a substitute for reported, or GAAP information . For a more complete explanation of the company's definition of non-GAAP please refer to its financial press releases. The GeoTeam® non-GAAP figures may, from time to time, differ from company supplied figures.

Guidance Report:

'With regard to our outlook for the current calendar year, I remain cautiously optimistic. While we may experience a slow-down in the small biopharma client segment due to the current condition of the financial markets, I believe that this impact may be offset by an increase in outsourcing levels from larger clients. In this regard, many large pharma companies are approaching clinical trials outsourcing more strategically, and look to benefit from our depth of expertise in the drug development process. Notwithstanding the current uncertain environment, we continue to believe that our strategy and position in the industry are sound, and feel that we are poised to take advantage of the many opportunities that continue to exist in the marketplace.'

Guidance for the third quarter of Fiscal Year 2009 (ending March 31, 2009)

 Guidance for the third Fiscal Year 2009 (ending June 31, 2009)

 * EPS Figures exclude gains and charges. (Non-GAAP).  EPS guidance appears to be slightly higher than analyst estimates.

Source: PR Newswire (January 26, 2009)